


- Combination therapy approved by the FDA in August 2018
- Treats those homozygous for the *F508del* mutation in the CFTR gene
- Increases chloride ion transport for treatment of cystic fibrosis
- Decreases mucus buildup in bronchial tubes




CFTR Potentiator: Ivacaftor

Potentiates the channel-open probability (channel gating) of CFTR at the cell surface

CFTR Corrector: Lumacaftor

Facilitates the processing and trafficking of CFTR to increase the amount of CFTR at the cell surface



Orkambi (Lumacaftor and Ivacaftor)

